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Abstract
Background
Older women are at the greatest risk of breast cancer development and a considerable num-
ber present with comorbidities. Although the majority of breast cancers in this age group
express oestrogen receptor (ER), which makes endocrine therapy (primary or adjuvant) fea-
sible, given the huge size of the elderly population, there remains a significant number of
patients, in absolute term, whose tumours do not express ER and their management is
challenging.
Methods
Of a consecutive series of 1,758 older (70 years) women with early operable primary
breast cancer managed in a dedicated service from 1973–2010, 252(14.3%) had ER-nega-
tive (histochemical (H) score50) tumours. Their clinical outcome was retrospectively
reviewed and tumour samples collected from diagnostic core biopsies were analysed for
progesterone receptor (PgR), HER2 and Ki67 using immunohistochemistry.
Results
The commonest primary treatment was surgery (N = 194, 77%) followed by primary endo-
crine therapy (14.3%), primary radiotherapy (5.6%) and supportive treatment only (3.1%).
Among the patients undergoing surgery, most of them had grade 3 (78.1%) and node-nega-
tive disease (62.2%). Some of them (21.1%) received postoperative radiotherapy. At a
median follow-up of 37.5 months, 117 patients had died, out of which 48.6% were due to
breast cancer. For those who underwent surgery, the regional and local recurrence rates
were 2% and 1.1% per annum respectively. For those who received primary endocrine
therapy, 38% progressed at 6 months, however all patients who had primary radiotherapy
achieved clinical benefit at 6 months. Regardless of treatment given, the 5-year breast
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cancer specific and overall survival rates were 70% and 50% respectively. Biological analy-
sis based on good quality needle core biopsy specimensfrom181 patients showed that
26.8% (N = 49), 16.9% (N = 31) and 70.7% (N = 70)expressed positivity for PgR, HER2 and
Ki67 respectively. No correlation between these biomarkers and breast cancer specific sur-
vival was demonstrated.
Conclusion
Oestrogen receptor negative early operable primary breast cancer in older women is associ-
ated with poor prognostic features in terms of biology and clinical outcome. Surgery appears
to produce the best outcome as a primary treatment, however for those where neither sur-
gery nor chemotherapy is appropriate, primary radiotherapy can be beneficial.
Introduction
The risk of developing breast cancer rises with advancing age and one-third of cases occur in
women over 70 years of age[1]. The highest life time probability of breast cancer development
was observed in women70 years of age (6.73%) as compared to their younger counterparts
where the probability reported was 1.44%, 2.39% and 3.40% respectively in the age groups of
<40, 40–50 and 51–60 years[2]. Despite this, most research efforts are directed towards youn-
ger patients. The currently available literature showsa remarkable lack or under-representation
of older women in clinical trials.
With increasing age there is evidence available showing a rise in oestrogen receptor (ER)
positivity, where over 80% of older (70 years) women tend to develop ER-positive tumours
[3], which are also considered as a less aggressive phenotype. However, given the size of the
elderly population, there still remain a significant number of women, in absolute terms,
who develop ER-negative tumours with possible poor prognosis. On the other hand, older
women show a high prevalence of comorbidities, where a considerable proportion are life-
threatening [4]. Patients with ER-positive tumours have endocrine therapy (primary or adju-
vant) as a viable option. However, those with ER-negative tumours still pose a therapeutic
challenge to clinicians. Partly because of their relatively small number (relative to their ER-pos-
itive counterparts within the elderly cohort), little is known about their biological characteris-
tics and long-term clinical outcome.
A UK-based audit of management protocols in older women with early operable primary
breast cancer reported that 40% of them were treated by non-operative therapy[5]. This fact
has impacted on how ER-negative primary breast cancer in older women could be studied.
Most of the available studies only include patients treated by surgery (often using surgical spec-
imens for studying biological features), introducing a potential bias towards a comparatively
fitter older population. If we were to encompass all older women with ER-negative tumours
regardless of primary treatment, we have to study their biological features using tumour tissue
obtained from diagnostic needle core biopsies. The limitations of such approach include the
small quantity and quality of the specimen, and method used to process the tissue (eg fresh fro-
zen or formalin fixed paraffin embedded tissues).
This study aimed to evaluate a series of ER-negative tumours from a large consecutive
cohort of older women with early operable primary breast cancer, regardless of their initial
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primary treatment, by analysing (1) their long-term clinical outcome; and (2) their biological
features in terms of progesterone receptor (PgR), human epidermal receptor (HER) 2 and
Ki67.
Patients and methods
The study involved 252 older (70 years of age) women with ER-negative early operable inva-
sive primary breast carcinoma (defined as T0-2, N0-1, M0) diagnosed between 1973 and 2010.
Data analysis using cut-offs of ER histochemical (H)-score of 0 and 50 (using immunohis-
tochemistry (IHC)) to define ER negativity showed no significant difference in clinical out-
come, thus for the purpose of this paper ER negativity was defined as H-score50. H-score
50 has been reported to have fairly low expression merely predicting endocrine response[6].
These patients were identified from a well characterised consecutive series of 1,758 (out of
which ER status was available in 1,380 patients) older women managed in a dedicated service
for early operable primary breast cancer at Nottingham University Hospitals, as previously
described in details[7, 8]. Briefly, patients were identified from a database in Histopathology
Department (using paper archive (before 1987) and computerised records recently). Clinical
data were then retrospectively collected from clinical notes. Basic histopathological character-
istics i.e. types, grades and ER status were based on standard reports of diagnostic needle
core biopsies by a single team of pathologists following the same pathological guidelines at
any time point. Axillary stage was defined according to the number of involved lymph nodes
in the surgical specimen (therefore only applicable to patients treated by primary surgery):
1 = 0 involved, 2 = 1–3 involved and 3 =4 involved[9].
There have been changes in the management guidelines over the period concerned, as pre-
viously described[7], however most of these changes were attributed to the use of endocrine
therapy in clinical practice, having minimal impact on the ER-negative group. Thus their gen-
eral management approach essentially remained the same throughout, though in the recent
decade the dedicated clinic had evolved to become a joint surgical/oncology facility, supported
by dedicated breast care nurses, with more structured multidisciplinary assessment. Regard-
less, all patients were offered surgery as primary therapy with axillary surgery as appropriate
(before year 2000 axillary surgery was only considered when there were clinically node positive
disease, while from 2000,level III axillary clearance was carried out for pre-operatively proven
node-positive cases), and four-node sampling, with introduction of blue dye-assisted sentinel
node biopsy in recent years, was performed in clinically node-negative cases. In the recent
decade, intact breast irradiation was given to all patients following wide local excision (WLE)
and post-mastectomy chest wall irradiation was given if two of the following three features
existed—grade 3, positive lymph nodes or vascular invasion. Adjuvant chemotherapy with/
without trastuzumab was recommended to comparatively fit patients based on their prognos-
tic features and HER2 status. Those who were unfit or refused to have surgery were then
assessed and offered primary radiotherapy as appropriate, using a variety of dose schedules
and techniques, all intended to deliver the biological equivalent of at least 70Gy in 35 fractions
to the site of the primary tumour, with lower doses to remaining ipsilateral breast tissue. His-
torically some patients received primary endocrine therapy (using tamoxifen or an aromatase
inhibitor such as anastrozole if they had contraindications to or were unable to tolerate tamox-
ifen). All patients were followed up on a regular basis except for those who were frail and/or
refused further follow-up, they were discharged back to the general practitioner (GP)’s care.
The outcome of all patients was analysed in terms of breast cancer specific survival and
overall survival, defined respectively as the interval from diagnosis to death from breast cancer,
and as the interval from diagnosis to death from any causes. Those treated by primary surgery
ER negative breast cancer in older women
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were assessed for time to local and regional recurrences, defined as the time from surgery to
appearance of the first local (in the intact breast for patients undergoing WLE, and in the ante-
rior chest wall for patients treated by mastectomy, all on the ipsilateral side) or regional (in the
ipsilateral axilla) recurrence respectively. Response to non-operative therapy was assessed clin-
ically by callipers, according to International Union Against Cancer (UICC) criteria and Brit-
ish Breast group recommendations [10, 11]. Complete response (CR) was defined as complete
disappearance of tumour, partial response (PR) as>50% reduction, stable disease (SD) as
<50% reduction or <25% increase, progressive disease (PD) as>25% increase in the bi-
dimensional product of the tumour. Appearance of a new tumour (including metastases) was
also categorised as PD. Clinical benefit (CB) was defined by CR/PR/SD for a minimum dura-
tion of 6 months[12].
Biological analysis of needle core biopsies
Out of 252 patients with ER-negative tumours, 181 sets of good quality needle core biopsy
specimens were available for biological analysis. Immunohistochemical (IHC) staining was
performed specifically for this study, for PgR, HER2 and Ki67 by using StreptAvidin Biotin
Complex (ABC) sequenza method, as previously described[13]. The description and the cut-
off points to define positivity of the markers are given in Table 1.
Statistical methods
Statistical analysis was carried out using Statistical Package for Social Sciences (SPSS, version
17, Chicago, Illinois). A p-value of<0.05 was considered significant. Time-dependant vari-
ables were analysed by using Kaplan-Meier method with application of Log-rank and Wil-
coxon tests of significance as appropriate.
Additional information required
Oestrogen receptor (ER) negative breast cancers in older women pose a clinical dilemma,
where the majority presents with a number of co-morbidities and related social issues. Cur-
rently there is limited literature available to guide in this regard. This study presents biological
characteristics and clinical outcome in a large series with ER negative breast cancers in older
women.
Ethics statement. The study was approved by the Research Ethics Committee at Notting-
ham City Hospital. The requirement for informed consent was waived.
Results
All patients
Patients’ characteristics and management pattern. As described above, a total of 252
patients were found to have ER negative tumours with H-score50, with the great majority
having no ER expression at all (H-score 0 = 90.5%, N = 228, H-score 1–50 = 9.5%, N = 24).
Out of these 71% were<80 years of age. The majority of them had grade 2 or3 tumours(45.4%
Table 1. Summary of immunohistochemistry methodology for biological analysis.
Primary antibody Source Dilution Incubation time Cut-off to define positivity
PgR Dako- Mouse monoclonal 1:100 45 minutes 1%
HER2 Dako-Rabbit and anti-human 1:250 45 minutes 3+
Ki67 Dako- MIB1 clone 1:300 45 minutes 10%
https://doi.org/10.1371/journal.pone.0188528.t001
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and 50.0% respectively) and invasive ductal carcinoma with no special type (NST) was the
most common histological type observed on needle core biopsy specimens (Table 2).
Most (N = 194, 77%) patients underwent surgery as their primary treatment (mastec-
tomy = 79.7%, WLE = 20.3%), with axillary surgery in 69.9% of them. The second most com-
mon primary treatment was primary endocrine therapy (N = 36, 14.3%), followed by primary
radiotherapy (N = 14, 5.6%). Eight (3.1%) patients did not have any active treatment and
received supportive care only.
Causes of death and survival analysis. At a median follow-up of 37.5 (longest 220)
months, 107 patients had died, of which 48.6% (N = 52) were from breast cancer (Table 3). A
relatively higher proportion of patients diagnosed at the age of<80 years died of breast cancer
(54.5% breast cancer deaths versus 45.5% non-breast cancer deaths), as compared to the older
patients (33.3% breast cancer deaths versus 66.7% non-breast cancer deaths). Among the non-
breast cancer deaths, a greater proportion (66.7% in80 versus 45.5% in <80) were observed
in the older (80 years) age group (p = 0.03). The 5-year breast cancer specific survival and
overall survival rates were 70% and 50% respectively (Fig 1).
Patients treated by surgery
Management pattern and clinical outcome. For those patients who underwent surgery
(N = 194),the majority had grade 3 as confirmed on operative histology (78.2%) and for those
who had axillary surgery, most of them (62.2%) had node-negative disease. Forty-one patients
(29.9%) had adjuvant radiotherapy and none of them received adjuvant chemotherapy.
After a median follow-up of 37.5 months,75 (38.7%) patients died, out of which 33 died
from breast cancer and the rest from non-breast cancer related causes. The 5-year breast can-
cer survival and overall survival rates were 80% and 61% respectively. The local and regional
recurrence rates were 2% and 1.1% per annum respectively (Table 2). There was no significant
difference between the rates of and time to local recurrence, regardless of whether they under-
went mastectomy or WLE. There was no significant difference in regional recurrence between
patients who had axillary surgery and those who did not (Fig 1).
Patients treated by non operative therapy. Fifty patients received non-operative therapy
including primary endocrine therapy (N = 36) and primary radiotherapy (N = 14).
Primary endocrine therapy. A total of 36 patients were put on primary endocrine ther-
apy; 27 (75.0%) had tumours with H-score 0 and the rest had H-score between 1–49. Response
status at 6 months was available in 26 patients, of which 15 (57.7%) achieved CB, 10 (38.5%)
progressed and one patient (3.8%) came off treatment due to intolerance. Eventually 25
patients progressed after a median duration of 6 months (longest 45 months). For those who
achieved CB, the median duration was 17 (range 9–45) months.
At a median follow-up of 23 (longest 103) months, 33 (91.7%) patients died. Among those
whose causes of death were known, 15 and 13 died of breast cancer and non-breast cancer
causes respectively.
Primary radiotherapy. A total of 14 patients received primary radiotherapy. After a
median follow-up of 15.5 months nine patients were still alive, three died from non-breast can-
cer causes (two of them died within 6 months) and two patients died of breast cancer. Within
6 months two patients died without progression and two were discharged back to GP’s care
thus the response status at 6 months was available in 10 patients. All of them achieved CB
(CR = 50%, PR = 40%, SD = 10%). At the time of analysis only three patients progressed
respectively at 9, 33 and 34 months (median time to progression = 33 months). The median
duration of CB was 34 months (longest 52 months). A summary of all patients, including their
survival, is given in Table 4.
ER negative breast cancer in older women
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Table 2. Patient and tumour characteristics and management pattern of ER-negative early operable
primary breast cancer in older women.
Number of patients Percentage (%)
Age (years) N = 252
70–79 179 71
More than 80 73 29
Clinical size of tumour (cm) N = 247
0(Screen detected) 14 5.7
0.1–2 57 23.0
2.1–5 176 71.3
Treatment groups N = 252
Surgery 194 77
Primary endocrine therapy 36 14.3
Primary radiotherapy 14 5.6
No treatment (supportive care only) 8 3.1
Pattern of surgical management N = 194
Mastectomy 155 79.7
WLE* 39 20.3
Axillary surgery 135 69.6
Adjuvant Radiotherapy
Adjuvant radiotherapy 41 29.9
Grade (based on core biopsies) N = 108
1 5 4.6
2 49 45.4
3 54 50.0
Grade (based on surgical specimen) N = 174
1 5 2.9
2 33 19.0
3 136 78.1
Axillary stage N = 135
1 84 62.2
2 29 21.5
3 22 16.3
Histological types (based on core biopsies) N = 193
Ductal carcinoma (including NST**) 162 84.2
Tubular mixed 5 2.5
Lobular 5 2.5
Mucinous 1 0.5
Other types 20 10.3
Biomarkers
PgR N = 183
Positive 49 26.8
Negative 134 73.2
HER2 N = 183
Positive 31 16.9
Negative 152 83.1
Ki67 N = 99
Positive 70 70.7
Negative 29 29.3
(Continued )
ER negative breast cancer in older women
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Table 2. (Continued)
Outcome Overall rate (%) Average rate per annum (%)
Local recurrence
All 10.4 2.0
Mastectomy group 8.4 1.0
WLE* 18.4 1.8
Regional recurrence
All 8.3 1.1
Axillary surgery 5.9 0.9
No axillary surgery 13.8 1.8
*Wide local excision,
**No special type
https://doi.org/10.1371/journal.pone.0188528.t002
Table 3. Causes of death by age groups in older women with ER-negative early operable primary
breast cancer.
Age groups Breast cancer deaths N (%) Non-breast cancer deaths N (%) Total p-value
All 52 (48.6) 55 (51.4) 107 0.08
70–79 years 42 (54.5) 35 (45.5) 77 0.42
80 years 10 (33.3) 20 (66.7) 30 0.06
https://doi.org/10.1371/journal.pone.0188528.t003
Fig 1. Kaplan-Meier plots of time-dependant outcome variables in older women with ER-negative early operable primary breast cancer. (A)
Breast cancer specific survival of Oestrogen receptor negative early operable primary breast cancer in older women. (B) Overall survival of Oestrogen
receptor negative early operable primary breast cancer in older women. (C) Local recurrence free survival of Oestrogen receptor negative early operable
primary breast cancer in older women- Mastectomy versus wide local excision. (D) Regional recurrence free survival of Oestrogen receptor negative early
operable primary breast cancer in older women- Axillary surgery versus no axillary surgery. (E) Breast cancer specific survival of Oestrogen receptor
negative early operable primary breast cancer in older women- Progesterone Receptor (PR) positive versus negative. (F) Breast cancer specific survival
of Oestrogen receptor negative early operable primary breast cancer in older women- Human Epidermal Growth Factor Receptor– 2 (HER2) positive
versus negative. (G) Breast cancer specific survival of Oestrogen receptor negative early operable primary breast cancer in older women- Ki67 positive
versus negative. (H) Breast cancer specific survival of Oestrogen receptor negative early operable primary breast cancer in older women- Low (ie 1–2)
Grade versus high (ie 3) Grade.
https://doi.org/10.1371/journal.pone.0188528.g001
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Biological analysis. As described, 185 patients had additional IHC analysis of further
biomarkers based on core biopsy specimens. Positive expression of PgR, HER2 and Ki67 was
observed respectively in 49 (26.8%), 31 (16.9%) and 70 (69.8%) patients. A summary of the
data is given in Table 2. None of the three markers showed significant influence on breast can-
cer specific survival (Fig 1).
Discussion
Results of the analysis showed that the majority of older women with ER-negative early opera-
ble primary breast cancer presented with larger tumour size, and high grade, ductal carcino-
mas. A great majority of them had primary surgery and only a small number was treated by
non-operative therapies. A considerable proportion died of breast cancer. For those treated by
primary surgery, the local and regional failure rates were low (approximately 2% and 1% per
annum respectively). For patients treated by non-operative means, the response to primary
endocrine therapy was poor, while primary radiotherapy was associated with a relatively
better outcome, However given the small number of patients, it would be difficult to draw a
conclusion.
Regardless of treatment pattern and biological markers, the absence of ER expression has
been shown to be associated with poor prognosis[8, 14]. The degree of ER positivity has been
reported in younger (<70 years) patients as a significant indicator of outcome[6]. Patients
who had tumours with poor ER expression (ie having a low H-score) showed poorer outcome
following surgery and adjuvant tamoxifen without any chemotherapy, when compared to
those with a higher ER H-score[6]. As described, therapeutic options for ER-negative tumours
in the elderly population, especially those with significant comorbidities, are limited. Individ-
ual randomised trials or even meta-analysis of large number of trials have not yet been able to
provide sufficient evidence for wide recommendation of chemotherapy in older women.
Table 4. Summary of patients with ER-negative early operable primary breast cancer treated by primary radiotherapy.
Patient
number
Age
(years)
ER H-
score
Response at 6
months
Progression
status
Time to progression
(months)
Second line
Therapy
Survival
(months)
Survival status at
last follow-up
1 70 0 CR No - - 14 Alive
2 70 0 CR No - - 52 Alive
3 73 0 PR2 No - - 9 Died from non BC
4 74 0 CR No - - 25 Alive
5 75 0 NA3 NA - - 30 Died from BC
6 79 0 PR Yes 9 Mastectomy 11 Alive
7 79 0 CR1 Yes 33 Tamoxifen 166 Died from BC4
8 79 0 SD No - - 9 Alive
9 80 0 NA Na - - 5 Died from non BC
10 81 0 NA NA - - 4 Died from non BC
11 81 0 NA NA - - 1 Alive
12 82 0 PR Yes 34 No treatment 69 Alive
13 85 20 PR No - - 17 Alive
14 91 0 CR No - - 26 Alive
1
= Complete response,
2
= Partial response,
3
= Not available*,
4
= Breast cancer
https://doi.org/10.1371/journal.pone.0188528.t004
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However the Oxford Overview showed that the number of patients >70 years available for
meta-analysis was limited[15].
In this series the majority of patients were treated by surgery with adjuvant radiotherapy
as appropriate but no adjuvant chemotherapy. Non-operative therapy, as reported by other
studies, is usually prescribed due to patients’ choice, ill health or in some cases extreme of age
which make surgery an inappropriate option[5, 16]. However to date very limited data are
available reporting on the role of non-operative therapy in this group of patients. In contrast
to the outcome of patients with ER-positive tumours as reported by our group previously
(from the large cohort of patients managed in the same dedicated service), where the majority
died of non breast cancer causes[8], the majority of those with ER-negative tumours studied
here died of breast cancer. The annual rates of local and regional recurrences were nearly dou-
ble when compared with that seen in ER positive tumours and also the survival outcome was
relatively poor (Table 5).
While this could indicate the aggressive tumour biology of ER-negative tumours, on the
other hand, it may suggest sub-optimal treatment. Not every patient in the series was able to
have surgery which was shown to be associated with the best outcome. Endocrine therapy does
not play any role in ER-negative tumours. High level evidence is scarce in supporting the use
of cytotoxic chemotherapy with or without trastuzumab in the elderly population.
In contrast to what was seen by our group in the ER-positive disease, the higher rates of
Ki67 expression, relatively lower proportion of PR expression and higher proportion of HER2
over-expression (as opposed to the ER positive tumours) in our study (Table 5)are consistent
with more aggressive tumour biology as reported in previous studies[14, 17–20].
With advancing age biological characteristics of breast cancer appear to change with high
rate of ER positivity, PR positivity and low HER2 and Ki67 expression in general[3], however
the extent of these changes is not yet clear in ER-negative tumours. Further studies in this
regard are strongly recommended. Those patients with HER2 over-expressing tumours have
trastuzumab as a potential therapeutic option. However available evidence has primarily been
drawn from studies focusing on younger patients, with no or under-representation of older
women and invariably all studies demonstrated the role of trastuzumab given in combination
with cytotoxic chemotherapy[21–23]. The presence of comorbidities, limited physiological
reserve and lack of social support may make chemotherapy very challenging in this group of
patients and trastuzumab mono-therapy could be very attractive though there is no evidence
to support its use at present.
The response to primary endocrine therapy appeared poor in general as compared to sur-
gery, which is not unexpected due to the relatively low ER expression and PgR expression
Table 5. Clinical outcome and expression of biomarkers in ER-negative versus ER-positive tumours in older women with early operable primary
breast cancer.
Age group ER negative (present study) ER positive(8)
Breast cancer deaths N(%) Non-breast cancer deaths N(%) Breast cancer deaths N(%) Non-breast cancer deaths N(%)
All 52 (48.6) 55(51.4) 105 (25.8) 302 (74.2)
70–79 years 42 (54.5) 35(45.4) 70 (34.7) 132 (65.3)
80 years 10 (33.3) 20(66.7) 35 (17.1) 170 (82.9)
Expression of biomarkers
Biomarker ER negative (present study) ER positive [17]
PR positive (%) 26.8 46
HER2 positive (%) 16.9 8
Ki67 positive (%) 70.7 64
https://doi.org/10.1371/journal.pone.0188528.t005
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(26.8%). However the use of primary endocrine therapy in this series was predominantly his-
torical (1970s and early 1980s mainly). Although primary radiotherapy has produced a com-
paratively better outcome, it would be difficult to draw a definite conclusion given the small
patient number. Nevertheless it could be considered as a therapeutic option for patients with
very limited life expectancy and when surgery is deemed inappropriate. Although there is lim-
ited data available showing the role of primary radiotherapy for early operable primary breast
cancer which is normally treated by primary surgery, it has been used in locally advanced breast
cancer[24]. Further studies in the future may be able to delineate its precise role in this selected
group of elderly patients. Two studies reported on hypo-fractionated radiotherapy (single
weekly dose of 6.5 Gy corresponding to 5 fractions, with total dose of 32.5–45.5 Gy) in combi-
nation with tamoxifen 20 mg in older women, given as primary therapy because they refused
surgery for their newly diagnosed primary breast cancer [25, 26]. Both studies included patients
of 64 years and older with T1-4, N0-1, M0 disease with a sample size of 70 (78% ER positive) in
one study and 115 (68% ER positive) in the other. The study by Maher et al, at a median fol-
low-up of 36 months, reported 10 deaths, out of which eight were due to breast cancer, giving a
3-year disease specific survival rate of 88%. Eleven patients developed loco-regional failure and
another 11 developed distant metastases, leaving 72% of patients disease free at the time of anal-
ysis [25]. The study by Courdi et al, at 41 months’ median follow-up, reported 15% (N = 19)
local failure and 78% 5-year local progression free survival, while the 5-year breast cancer spe-
cific survival rate was 71% [26]. Given that tamoxifen was used alongside radiotherapy in both
studies, it would be difficult to extract the precise effect of primary radiotherapy. Regardless
there is a possible role of radiotherapy (in full dose or in hypofractionation form) in this con-
text, but a definitive recommendation is not possible with such limited data.
In conclusion, older women with ER negative early operable primary breast cancer
appeared to have poor prognosis, however those treated by surgery or primary radiotherapy
had relatively better outcome, while primary endocrine therapy was associated with poor out-
come. Regardless of treatment the majority of patients died of breast cancer. The results of this
study strongly recommend consideration of primary surgery in most patients if comorbidities
allow, and further studies to explore the precise role of chemotherapy and trastuzumab,. Other
less toxic biological therapies should also be explored as potential therapeutic options. Primary
radiotherapy may also be used as an alternative to surgery in selected cases. Hypofractionated
schedules of radiotherapy, entailing far fewer hospital visits than previously given, are much
more attractive for these patients, and increasing hypofractionation (use of even fewer, but
larger individual fractions) is currently being evaluated in many centres.
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